Data disclosure in Zambia

1,248 views
1,186 views

Published on

Presentation by Owas Mwape, MeTA Zambia Council Member during the country sharing meeting, London 2009.

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,248
On SlideShare
0
From Embeds
0
Number of Embeds
6
Actions
Shares
0
Downloads
3
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Title of presentation 18/01/10 MeTA
  • Data disclosure in Zambia

    1. 1. Owas Mwape Council Member Data Disclosure in Zambia MeTA 18/01/10
    2. 2. Type of data being collected <ul><li>Policies, practices and results on </li></ul><ul><ul><li>Registration </li></ul></ul><ul><ul><li>Availability </li></ul></ul><ul><ul><li>Pricing </li></ul></ul><ul><ul><li>Promotion </li></ul></ul>18/01/10 MeTA
    3. 3. Overview of disclosure process and engagement of stakeholders  <ul><li>How is the data being disclosed? </li></ul><ul><li>Data is being disclosed through interviews with key informants in the pharmaceutical sector </li></ul><ul><li>Are the stakeholders involved? How? </li></ul><ul><li>The stakeholders are involved in the process both as data collectors and as key informants </li></ul>18/01/10 MeTA
    4. 4. Challenges & lessons Learned <ul><li>Brief overview of the main challenges </li></ul><ul><li>Bureaucracy </li></ul><ul><li>Unavailability of key informants </li></ul><ul><li>Unavailability of data (publications, etc) </li></ul><ul><li>General suspicion (why is this information being collected) </li></ul><ul><li>General lack of transparency in the medical field (confidentiality seems to apply in the sector) </li></ul><ul><li>Common view that the public lack interest in such matters and therefore there is no need for information to be in the public domain </li></ul><ul><li>What are the lessons learned so far? </li></ul><ul><li>There is need for increased lobbying for full data disclosure in pharmaceutical sector </li></ul><ul><li>Need for full commitment to MeTA principles from stakeholders </li></ul><ul><li>Bureaucracy is still a major challenge!!!! </li></ul>18/01/10 MeTA
    5. 5. Type of support needed <ul><li>Strategies for ensuring full commitment of all stakeholders to the MeTA principle of increased transparency </li></ul><ul><li>MeTA International to advise on how other countries have managed to link up to up to the national health reform process with health summits and joint evaluation </li></ul>18/01/10 MeTA
    6. 6. Thank you! <ul><li>Owas Mwape </li></ul><ul><li>oramwa@yahoo.com/ </li></ul><ul><li>+260 955 857 161 </li></ul>18/01/10 MeTA

    ×